437 related articles for article (PubMed ID: 33825804)
1. Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis.
Loft N; Egeberg A; Rasmussen MK; Bryld LE; Nissen CV; Dam TN; Ajgeiy KK; Iversen L; Skov L
JAMA Dermatol; 2021 Jun; 157(6):676-683. PubMed ID: 33825804
[TBL] [Abstract][Full Text] [Related]
2. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).
Phan DB; Bewley AP; Smith CH; Mackenzie T; Griffiths CEM; Lunt M; Warren RB; Yiu ZZN
Br J Dermatol; 2023 Jul; 189(1):62-70. PubMed ID: 37016153
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial.
Nabi H; Georgiadis S; Loft AG; Hendricks O; Jensen DV; Andersen M; Chrysidis S; Colic A; Danebod K; Hussein MR; Kalisz MH; Kristensen S; Lomborg N; Manilo N; Munk HL; Pedersen JK; Raun JL; Mehnert F; Krogh NS; Hetland ML; Glintborg B
Ann Rheum Dis; 2021 Nov; 80(11):1400-1409. PubMed ID: 33926921
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
[TBL] [Abstract][Full Text] [Related]
5. Drug survival and safety of biosimilars and originator adalimumab in the treatment of psoriasis: a multinational cohort study.
Phan DB; Jourdain H; González-Quesada A; Zureik M; Rivera-Díaz R; Sahuquillo-Torralba A; Descalzo-Gallego MA; Lunt M; Garcia-Doval I; Sbidian E; Warren RB; Yiu ZZN
BMJ Open; 2023 Jul; 13(7):e075197. PubMed ID: 37451726
[TBL] [Abstract][Full Text] [Related]
6. Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study.
Casanova MJ; Nantes Ó; Varela P; Vela-González M; Rivero M; Sierra-Gabarda O; Riestra S; Barreiro-de Acosta M; Martín-Rodríguez MDM; Gargallo-Puyuelo CJ; Reygosa C; Muñoz R; de la Filia-Molina IG; Núñez-Ortiz A; Kolle L; Calafat M; Huguet JM; Iglesias-Flores E; Martínez-Pérez TJ; Bosch O; Duque-Alcorta JM; Frago-Larramona S; Van Domselaar M; González-Cosano VM; Bujanda L; Rubio S; Mancebo A; Castro B; García-López S; de Francisco R; Nieto-García L; Laredo V; Gutiérrez-Casbas A; Mesonero F; Leo-Carnerero E; Cañete F; Ruiz L; Gros B; Del Moral-Martínez M; Rodríguez C; Chaparro M; Gisbert JP
Aliment Pharmacol Ther; 2023 Jul; 58(1):60-70. PubMed ID: 37089065
[TBL] [Abstract][Full Text] [Related]
7. Biosimilars for the Treatment of Psoriasis: A Systematic Review of Clinical Trials and Observational Studies.
Phan DB; Elyoussfi S; Stevenson M; Lunt M; Warren RB; Yiu ZZN
JAMA Dermatol; 2023 Jul; 159(7):763-771. PubMed ID: 37256582
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study.
Scrivo R; Castellani C; Mancuso S; Sciarra G; Giardina F; Bevignani G; Ceccarelli F; Spinelli FR; Alessandri C; Di Franco M; Riccieri V; Priori R; Conti F
Clin Exp Rheumatol; 2023 Mar; 41(3):613-619. PubMed ID: 35916302
[TBL] [Abstract][Full Text] [Related]
9. Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost-effectiveness?
Roccuzzo G; Rozzo G; Burzi L; Repetto F; Dapavo P; Ribero S; Quaglino P
Dermatol Ther; 2022 Nov; 35(11):e15803. PubMed ID: 36062429
[TBL] [Abstract][Full Text] [Related]
10. Outcomes after anti-tumour necrosis factor originator to biosimilar switching in children and young people with juvenile idiopathic arthritis in the UK: a national cohort study.
Kearsley-Fleet L; Baildam E; Beresford MW; Douglas S; Foster HE; Southwood TR; Hyrich KL;
Lancet Rheumatol; 2024 Jul; 6(7):e438-e446. PubMed ID: 38843858
[TBL] [Abstract][Full Text] [Related]
11. Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease - a prospective, multicentre study.
Lontai L; Gonczi L; Balogh F; Komlodi N; Resal T; Farkas K; Molnar T; Miheller P; Golovics PA; Schafer E; Szamosi T; Ilias A; Lakatos PL
Dig Liver Dis; 2022 Dec; 54(12):1639-1645. PubMed ID: 35931624
[TBL] [Abstract][Full Text] [Related]
12. Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden.
Di Giuseppe D; Lindstrom U; Bower H; Delcoigne B; Frisell T; Chatzidionysiou K; Sjöwall C; Lindqvist E; Askling J
Rheumatology (Oxford); 2022 Aug; 61(9):3596-3605. PubMed ID: 34919663
[TBL] [Abstract][Full Text] [Related]
13. A switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn's disease: an analysis of two propensity score-matched cohorts.
Lukas M; Kolar M; Reissigova J; Duricova D; Machkova N; Hruba V; Lukas M; Vasatko M; Jirsa J; Pudilova K; Malickova K
Scand J Gastroenterol; 2022 Jul; 57(7):814-824. PubMed ID: 35234552
[TBL] [Abstract][Full Text] [Related]
14. OBSIDIAN - real-world evidence of originator to biosimilar drug switch in juvenile idiopathic arthritis.
Maccora I; Lombardi N; Crescioli G; Bettiol A; Bonaiuti R; Pagnini I; Maniscalco V; Marrani E; Mastrolia MV; Ravaldi C; Consolini R; Cattalini M; Vannacci A; Simonini G
Rheumatology (Oxford); 2022 Apr; 61(4):1518-1528. PubMed ID: 34273158
[TBL] [Abstract][Full Text] [Related]
15. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.
Lindström U; Glintborg B; Di Giuseppe D; Nordström D; Aarrestad Provan S; Gudbjornsson B; Askling J; Lund Hetland M; Aaltonen K; Krogh NS; Geirsson AJ; Jacobsson LTH
RMD Open; 2019; 5(2):e001079. PubMed ID: 31749988
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts.
Derikx LAAP; Dolby HW; Plevris N; Lucaciu L; Rees CS; Lyons M; Siakavellas SI; Constantine-Cooke N; Jenkinson P; Su S; O'Hare C; Kirckpatrick L; Merchant LM; Noble C; Arnott ID; Jones GR; Lees CW
J Crohns Colitis; 2021 Dec; 15(12):2011-2021. PubMed ID: 34089587
[TBL] [Abstract][Full Text] [Related]
17. Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis.
Gisondi P; Geat D; Armeni P; Bellinato F; Maurelli M; Girolomoni G
Expert Opin Biol Ther; 2022 Dec; 22(12):1579-1584. PubMed ID: 35466843
[TBL] [Abstract][Full Text] [Related]
18. Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre.
Lukas M; Malickova K; Kolar M; Bortlik M; Vasatko M; Machkova N; Hruba V; Duricova D; Lukas M
J Crohns Colitis; 2020 Jul; 14(7):915-919. PubMed ID: 31905382
[TBL] [Abstract][Full Text] [Related]
19. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis.
Egeberg A; Ottosen MB; Gniadecki R; Broesby-Olsen S; Dam TN; Bryld LE; Rasmussen MK; Skov L
Br J Dermatol; 2018 Feb; 178(2):509-519. PubMed ID: 29094341
[TBL] [Abstract][Full Text] [Related]
20. An Update Review of Biosimilars of Adalimumab in Psoriasis - Bioequivalence and Interchangeability.
Zhou X; Chen Z; Bi X
Drug Des Devel Ther; 2021; 15():2987-2998. PubMed ID: 34267501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
